CSNK2B and congenital myasthenic syndrome: Through a rigorous experimental and bioinformatic approach combining RNA-Seq–based screen, data filtering/prioritization, experimental validation, and rescue assays, we demonstrate that CSNK2B is a critical downstream mediator of HIKER/LINC02228 in excessive erythropoiesis in CMS patients.